See All Slides - tctmd.com

Slides

Presentation ESC 2018

Percutaneous Repair with the MitraClip Device for Severe Secondary Mitral Regurgitation

Presenter: Jean François Obadia

August 28, 2018

Presentation ESC 2018

Advanced managment of patients with Cardiogenic Shock

Presenter: Pascal Vranckx

August 27, 2018

ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo

Presentation ESC 2018

ASCEND A Randomized Trial of Omega-3 Fatty Acids (fish oil) vs Placebo

Presenter: Jane Armitage

August 27, 2018

Presentation ESC 2018

ASCEND Randomized placebo-controlled trial of aspirin

Presenter: Jane Armitage

August 27, 2018

Presentation ESC 2018

Durability of Transcatheter Heart Valves - Worse, Similar, or Better than Surgical Valves?

Presenter: Davide Capodanno

August 27, 2018

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

Presentation ESC 2018

FUnctional Testing Underlying REvascularization The FUTURE trial

Presenter: Gilles Rioufol

August 26, 2018

Presentation ESC 2018

CULPRIT-SHOCK: Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock – 1-Year Results

Presenter: Holger Thiele

August 26, 2018

Presentation ESC 2018

The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX

Presenter: Marco Valgimigli

August 26, 2018

Presentation

COAPT Entry Criteria

August 21, 2018

Advertisement

Slides

Percutaneous Repair with the MitraClip Device for Severe Secondary Mitral Regurgitation

Advanced managment of patients with Cardiogenic Shock

ASCEND A Randomized Trial of Omega-3 Fatty Acids (fish oil) vs Placebo

ASCEND Randomized placebo-controlled trial of aspirin

Durability of Transcatheter Heart Valves - Worse, Similar, or Better than Surgical Valves?

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

FUnctional Testing Underlying REvascularization The FUTURE trial

CULPRIT-SHOCK: Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock – 1-Year Results

The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX

COAPT Entry Criteria

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content